May 8, 2018 / 10:37 AM / 2 months ago

BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33

May 8 (Reuters) - Merrimack Pharmaceuticals Inc:

* Q1 OPERATING LOSS PER SHARE $1.33

* THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES

* MERRIMACK - BELIEVE CASH,CASH EQUIVALENTS OF $76.3 MILLION AS OF MARCH 31&SOME MILESTONE PAYMENTS ANTICIPATED FROM SHIRE TO BE ENOUGH TO FUND INTO H2 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below